Highlights of the Small Molecules Platform
From Discovery to Dose: Advancing Small Molecule & Highly Potent Platform Drug Substance
CordenPharma advances small molecule and highly potent API programs from discovery to commercial supply through deep expertise, expanded global capacity, and science-driven development. In 2025, major investments across our Liestal (CH), Chenôve (FR), Bergamo (IT), and Colorado (US) sites added new purification and development capabilities, large-scale reactors, state-of-the-art manufacturing lines, upgraded containment, and enhanced hydrogenation infrastructure providing substantial ready-to-use capacity for standard and highly potent APIs.
Our integrated services span route scouting, process optimization, solid-state design, continuous and flow chemistry, and advanced purification technologies, supported by robust analytical tools and QbD-based tech transfer. With secure high-potency containment down to 0.05 µg/m³ and expertise in complex chemistries including electro- and photochemistry, we deliver scalable, high-quality drug substance solutions that help innovators reduce risk, accelerate timelines, and reliably advance therapies from discovery to patients.
The Benefits of Our Flow Chemistry Services
Bringing Molecule to Market: Small Molecule & Highly Potent Platform Drug Products
In 2025, CordenPharma expanded its global Small Molecule and Highly Potent Drug Product capabilities with new OSD capacity in Plankstadt (DE), including a medium-scale line for non-potent and highly potent compounds down to <0.05 µg/m³, enabling flexible development and commercial production of complex tablets, capsules, and minitablets. Additional enhancements in Lisbon (PT), with new roller compactors and tablet coaters and expanded oral liquid filling at Fribourg (CH), combined with extensive packaging capabilities, provide end-to-end supply to over 70 countries. Our structured, phase-appropriate approach supports the full lifecycle of small molecule and peptide drug products, from early formulation and clinical supply through validation and commercial manufacturing, with expertise in granulation, compression, coating, encapsulation, and modified-release technologies.
Integrated API–Drug Product collaboration with our Solid State Centre of Excellence ensures optimal API form selection and smooth scale-up, while advanced developability, screening, and ASAP stability programs accelerate progression into FIH studies. Complemented by robust oral peptide delivery technologies, such as permeation enhancers, SMEDDS, and LNP carriers, these capabilities enable reliable advancement from early development to commercial supply, exemplified by our 2025 partnership with Viking Therapeutics for the manufacture of one billion oral solid peptide tablets.
Oral Solid Dose GMP Manufacturing for Clinical & Commercial Supply
Download Our Small Molecules Brochures
